ORIC Pharmaceuticals, Inc.
ORIC
$4.98
-$0.33-6.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.08M | 7.60M | 7.12M | 7.08M | 7.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.72M | 39.57M | 38.32M | 36.02M | 28.99M |
| Operating Income | -32.72M | -39.57M | -38.32M | -36.02M | -28.99M |
| Income Before Tax | -30.02M | -36.31M | -34.57M | -31.96M | -25.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.02M | -36.31M | -34.57M | -31.96M | -25.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.02M | -36.31M | -34.57M | -31.96M | -25.01M |
| EBIT | -32.72M | -39.57M | -38.32M | -36.02M | -28.99M |
| EBITDA | -32.42M | -39.27M | -38.05M | -35.75M | -28.73M |
| EPS Basic | -0.42 | -0.51 | -0.49 | -0.45 | -0.37 |
| Normalized Basic EPS | -0.26 | -0.32 | -0.31 | -0.28 | -0.23 |
| EPS Diluted | -0.42 | -0.51 | -0.49 | -0.45 | -0.37 |
| Normalized Diluted EPS | -0.26 | -0.32 | -0.31 | -0.28 | -0.23 |
| Average Basic Shares Outstanding | 71.04M | 70.65M | 70.54M | 70.35M | 67.35M |
| Average Diluted Shares Outstanding | 71.04M | 70.65M | 70.54M | 70.35M | 67.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |